
Ionis wins EU approval for TRYNGOLZA sHTG
Key points
- Ionis Pharmaceuticals (NASDAQ:IONS) received European Commission approval for TRYNGOLZA (olezarsen) to treat adults with severe hypertriglyceridemia and triglyceride levels of at least 880 mg/dL.
- The approval expands TRYNGOLZA's European indication, with approximately 700,000 people across the EU5 estimated to have triglyceride levels at or above the approved threshold.
- Phase 3 CORE and CORE2 studies demonstrated triglyceride reductions of up to 72% and an 85% reduction in acute pancreatitis events compared with placebo.
Ionis Pharmaceuticals (NASDAQ:IONS) received European Commission approval for TRYNGOLZA (olezarsen) to treat adults with severe hypertriglyceridemia and fasting triglyceride levels of at least 880 mg/dL (10 mmol/L).
The approval expands TRYNGOLZA's existing European marketing authorization for familial chylomicronemia syndrome into a broader patient population at increased risk of acute pancreatitis.
The decision follows Phase 3 CORE and CORE2 results, which demonstrated placebo-adjusted triglyceride reductions of up to 72% at six months and an 85% reduction in acute pancreatitis events over 12 months in a pooled analysis.
Approximately 700,000 people across France, Germany, Italy, Spain and the United Kingdom are estimated to have triglyceride levels of at least 880 mg/dL, according to the company's cited EU5 population estimates.
Ionis developed TRYNGOLZA and commercializes it in the United States, while Sobi holds exclusive commercialization rights outside the United States, excluding Canada and China, following the partners' licensing agreement.



